Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome

References

• AzzizR, WoodsKS, ReynaR, KeyTJ, KnochenhauerES, YildizBO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab2004;89:2745–2749.
   PubMed Web of Science ®Google Scholar
• KnochenhauerES, KeyTJ, Kahsar-MillerM, WaggonerW, BootsLR, AzzizR. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab1998;83:3078–3082.
   PubMed Web of Science ®Google Scholar
• BalenAH, ConwayGS, KaltsasG, TechatrasakK, ManningPJ, WestC, JacobHS. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod1995;10:2107–2111.
   PubMed Web of Science ®Google Scholar
• BookCB, DunaifA. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab1999;84:3110–3116.
   PubMed Web of Science ®Google Scholar
• LegroRS, KunselmanAR, DodsonWC, DunaifA. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab1999;84:165–169.
   PubMed Web of Science ®Google Scholar
• RizzoM, BerneisK, HersbergerM, PepeI, Di FedeG, RiniGB, SpinasGA, CarminaE. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod2009;24:2286–2292.
   PubMed Web of Science ®Google Scholar
• HolteJ, GennarelliG, BerneC, BerghT, LithellH. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?Hum Reprod1996;11:23–28.
   PubMed Web of Science ®Google Scholar
• GlueckCJ, PapannaR, WangP, GoldenbergN, Sieve-SmithL. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism2003;52:908–915.
   PubMed Web of Science ®Google Scholar
• BhattacharyaSM, GhoshM. Insulin resistance and adolescent girls with polycystic ovary syndrome. J Pediatr Adolesc Gynecol2010;23:158–161.
   PubMed Web of Science ®Google Scholar
• NapoliC, IgnarroLJ. Nitric oxide and atherosclerosis. Nitric Oxide2001;5:88–97.
   PubMed Web of Science ®Google Scholar
• SchulzeF, LenzenH, HanefeldC, BartlingA, OsterzielKJ, GoudevaL, Schmidt-LuckeC, KususM, MaasR, SchwedhelmE, Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J2006;152:493 e1–493 e8.
   Web of Science ®Google Scholar
• BogerRH, SydowK, BorlakJ, ThumT, LenzenH, SchubertB, TsikasD, Bode-BogerSM. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res2000;87:99–105.
   PubMed Web of Science ®Google Scholar
• FaraciFM, BrianJEJr, HeistadDD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol1995;269:H1522–H1527.
   Google Scholar
• AchanV, BroadheadM, MalakiM, WhitleyG, LeiperJ, MacAllisterR, VallanceP. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol2003;23:1455–1459.
   PubMed Web of Science ®Google Scholar
• CalverA, CollierJ, LeoneA, MoncadaS, VallanceP. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens1993;7:193–194.
   PubMed Web of Science ®Google Scholar
• ArdigoD, StuehlingerM, FranziniL, ValtuenaS, PiattiPM, PachingerO, ReavenGM, ZavaroniI. ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. Eur J Clin Invest2007;37:263–269.
   PubMed Web of Science ®Google Scholar
• BogerRH, LentzSR, Bode-BogerSM, KnappHR, HaynesWG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond)2001;100:161–167.
   PubMed Web of Science ®Google Scholar
• DayalS, LentzSR. ADMA and hyperhomocysteinemia. Vasc Med2005;10(Suppl 1):S27–S33.
   Web of Science ®Google Scholar
• VallanceP, LeoneA, CalverA, CollierJ, MoncadaS. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet1992;339:572–575.
   PubMed Web of Science ®Google Scholar
• CavusogluE, RuwendeC, ChopraV, PoludasuS, YanamadalaS, FrishmanWH, EngC, PinskyDJ, MarmurJD. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis2010;210:226–231.
   PubMed Web of Science ®Google Scholar
• LeongT, ZylbersteinD, GrahamI, LissnerL, WardD, FogartyJ, BengtssonC, BjorkelundC, ThelleD. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol2008;28:961–967.
   PubMed Web of Science ®Google Scholar
• BogerRH, SullivanLM, SchwedhelmE, WangTJ, MaasR, BenjaminEJ, SchulzeF, XanthakisV, BenndorfRA, VasanRS, Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation2009;119:1592–1600.
   PubMed Web of Science ®Google Scholar
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril2004;81:19–25.
   PubMed Web of Science ®Google Scholar
• GreenLC, WagnerDA, GlogowskiJ, SkipperPL, WishnokJS, TannenbaumSR. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem1982;126:131–138.
   PubMed Web of Science ®Google Scholar
• FaloiaE, CanibusP, GattiC, FrezzaF, SantangeloM, GarrapaGG, BoscaroM. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest2004;27:429.
   PubMed Web of Science ®Google Scholar
• EltingMW, KorsenTJ, SchoemakerJ. Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinaemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome. Clin Endocrinol (Oxf)2001;55:767–776.
   PubMed Web of Science ®Google Scholar
• GlueckCJ, MorrisonJA, FriedmanLA, GoldenbergN, StroopDM, WangP. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents. Metabolism2006;55:508–514.
   PubMed Web of Science ®Google Scholar
• CharitidouC, FarmakiotisD, ZournatziV, PidoniaI, PegiouT, KaramanisN, HatzistilianouM, KatsikisI, PanidisD. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis2008;196:958–965.
   PubMed Web of Science ®Google Scholar
• OzgurtasT, OktenliC, DedeM, TapanS, KenarL, SanisogluSY, YesilovaZ, YenenMC, ErbilMK, BaserIY. Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis2008;200: 336–344.
   PubMed Web of Science ®Google Scholar
• HeutlingD, SchulzH, NickelI, KleinsteinJ, KaltwasserP, WestphalS, MittermayerF, WolztM, KrzyzanowskaK, RandevaH, Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab2008;93:82–90.
   PubMed Web of Science ®Google Scholar
• MoranLJ, HutchisonSK, MeyerC, ZoungasS, TeedeHJ. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. Clin Sci (Lond)2009;116:761–770.
   PubMed Web of Science ®Google Scholar
• RajendranS, WilloughbySR, ChanWP, LibertsEA, HeresztynT, SahaM, MarberMS, NormanRJ, HorowitzJD. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis2009;204:509–514.
   PubMed Web of Science ®Google Scholar
• DemirelF, BideciA, CinazP, CamurdanMO, BiberogluG, YesilkayaE, HasanogluA. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. Clin Endocrinol (Oxf)2007;67:129–134.
   PubMed Web of Science ®Google Scholar
• PamukBO, TorunAN, KulaksizogluM, ErtugrulD, CiftciO, KulaksizogluS, YildirimE, DemiragNG. Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters. Fertil Steril2010;93:1227–1233.
   PubMed Web of Science ®Google Scholar
• KayaC, PabuccuR, KocaC, OguzAK, ErkanAF, KorkmazA, ErbasD. Relationship between interleukin-6 levels and ambulatory blood pressure in women with polycystic ovary syndrome. Fertil Steril, in press.
   Web of Science ®Google Scholar
• KaradenizM, ErdoganM, TamselS, ZengiA, AlperGE, CaglayanO, SaygiliF, YilmazC. Oxidative stress markers in young patients with polycystic ovary syndrome, the relationship between insulin resistances. Exp Clin Endocrinol Diabetes2008;116:231–235.
   PubMed Web of Science ®Google Scholar
• NaculAP, AndradeCD, SchwarzP, de BittencourtPIJr, SpritzerPM. Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity. Eur J Obstet Gynecol Reprod Biol2007;133:191–196.
   PubMed Web of Science ®Google Scholar
• WalchK, KolbusA, Hefler-FrischmuthK. Polymorphisms of the endothelial nitric oxide synthase gene in premenopausal women with polycystic ovary syndrome. Maturitas2008;61:256–259.
   PubMed Web of Science ®Google Scholar
• PalmF, OnozatoML, LuoZ, WilcoxCS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol2007;293:H3227–H3245.
   PubMed Web of Science ®Google Scholar
• ItoA, TsaoPS, AdimoolamS, KimotoM, OgawaT, CookeJP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation1999;99:3092–3095.
   PubMed Web of Science ®Google Scholar
• StuhlingerMC, TsaoPS, HerJH, KimotoM, BalintRF, CookeJP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation2001;104:2569–2575.
   PubMed Web of Science ®Google Scholar
• ZhangWZ, VenardosK, Chin-DustingJ, KayeDM. Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress. Hypertension2006;48:278–285.
   PubMed Web of Science ®Google Scholar
• WijeyaratneCN, NirantharakumarK, BalenAH, BarthJH, SheriffR, BelchetzPE. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity?Clin Endocrinol (Oxf)2004;60:560–567.
   PubMed Web of Science ®Google Scholar
• SchachterM, RazielA, FriedlerS, StrassburgerD, BernO, Ron-ElR. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod2003;18:721–727.
   PubMed Web of Science ®Google Scholar
• MacutD, DamjanovicS, PanidisD, SpanosN, GlisicB, PetakovM, RoussoD, KourtisA, BjekicJ, MilicN. Oxidised low-density lipoprotein concentration – early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol2006;155:131–136.
   PubMed Web of Science ®Google Scholar
• CarminaE, ChuMC, LongoRA, RiniGB, LoboRA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab2005;90:2545–2549.
   PubMed Web of Science ®Google Scholar
• WeltCK, GudmundssonJA, ArasonG, AdamsJ, PalsdottirH, GudlaugsdottirG, IngadottirG, CrowleyWF. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab2006;91: 4842–4848.
   PubMed Web of Science ®Google Scholar